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Abstract
Background: Several hydrolyzed cow’s milk (CM) formulas are available for
avoidance of allergic reactions in CM-allergic children and for prevention of
allergy development in high-risk infants. Our aim was to compare CM formulas
regarding the presence of immunoreactive CM components, IgE reactivity, aller-
genic activity, ability to induce T-cell proliferation, and cytokine secretion.
Methods: A blinded analysis of eight CM formulas, one nonhydrolyzed, two partially
hydrolyzed (PH), four extensively hydrolyzed (EH), and one amino acid formula,
using biochemical techniques and specific antibody probes was conducted. IgE reactiv-
ity and allergenic activity of the formulas were tested with sera from CM-allergic
patients (n = 26) in RAST-based assays and with rat basophils transfected with the
human FceRI, respectively. The induction of T-cell proliferation and the secretion of
cytokines in Peripheral blood mononuclear cell (PBMC) culture from CM allergic
patients and nonallergic individuals were assessed.
Results: Immune-reactive a-lactalbumin and b-lactoglobulin were found in the
two PH formulas and casein components in one of the EH formulas. One PH
formula and the EH formula containing casein components showed remaining
IgE reactivity, whereas the other hydrolyzed formulas lacked IgE reactivity. Only
two EH formulas and the amino acid formula did not induce T-cell proliferation
and proinflammatory cytokine release. The remaining formulas varied regarding
the induction of Th2, Th1, and proinflammatory cytokines.
Conclusion: Our results show that certain CM formulas without allergenic and
low proinflammatory properties can be identified and they may also explain dif-
ferent outcomes obtained in clinical studies using CM formulas.
Abbreviations
CM, cow’s milk; IgE, immunoglobulin E; RBL, rat basophil leukemia; rlf, recombinant lactoferrin; ra-la, recombinant alpha-lactalbumin;
raS1-cas, recombinant alphaS1-casein; rαS2-cas, recombinant alphaS2-casein; rb-cas, recombinant beta-casein; rb-lg, recombinant
beta-lactoglobulin; rj-cas, recombinant kappa-casein.
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Allergy
Food allergy is increasing and represents an important public
health problem (1, 2). Cow’s milk (CM) is one of the most
important allergen sources particularly in children and can
elicit severe life-threatening reactions in sensitized patients (3,
4). The molecular nature of CM allergens and the allergic
immune responses in terms of antibody and cellular
responses are subject of several studies with the goal to
develop diagnostic, therapeutic, and preventive strategies for
CM allergy (5).
For children who cannot be breastfed, the use of hydro-
lyzed CM formulas has been recommended for the preven-
tion of allergic reactions to CM in allergic children (i.e. for
treatment) as well as for the prevention of allergic sensitiza-
tion and allergy development in high-risk children (6–9).
Cow’s milk formulas differ regarding the degree of hydrol-
ysis of the milk proteins as well as regarding the hydrolysis
procedure ranging from partially to extensively hydrolyzed
(EH) formulas. Amino acid substitutes are available for
highly CM-allergic infants. Furthermore, CM formulas are
named depending on their protein source, such as whey or
casein hydrolyzates (10). Partially hydrolyzed (PH) formulas
are supposed to contain small and larger oligopeptides with a
molecular weight of <5 kDa, EH formulas should contain
only peptides with a molecular weight of <3 kDa, and amino
acid-based formulas (AA) are made of essential and
nonessential amino acids (10).
In a series of early intervention studies using hydrolyzed
CM formulas, it could be shown that certain formulas were
useful for allergy prevention in the first year of life (11) and
reduced the incidence of atopic dermatitis (AD) at the age of
3 and 6 years and this preventive effect persisted until the
age of 10 years without rebound (12–14).
Here, we conducted a blinded analysis of eight CM formu-
las: one nonhydrolyzed, two PH, four EH, and one amino
acid formula, regarding their biochemical composition, the
presence of antibody-reactive CM allergens/allergen frag-
ments, IgE reactivity, abilities to induce basophil activation,
T-cell proliferation, and secretion of a panel of different cyto-
kines. Our study revealed major differences among the for-
mulas regarding the presence of immunogenic allergens/
allergen fragments, IgE reactivity, allergenic activity, induc-
tion of T-cell responses, and cytokine secretion. In particular,
we were able to demonstrate a strongly varying capacity of
the formulas to induce the secretion of Th1, Th2, and other
proinflammatory cytokines. Our results may provide not only
an explanation for the selective effects of CM formulas on
the prevention of allergic sensitization and certain allergic
manifestations. They also indicate that CM formulas with
low proinflammatory activity can be identified, which may
have potential for prevention of other inflammatory diseases.
Materials and methods
Biological materials
In total, 10 coded CM formulas were analyzed in a blinded
manner regarding their biochemical and immunological char-
acteristics. Only after completion of the analysis, their iden-
tity was disclosed. Table 1 provides a summary and
characterization of the 10 CM formulas regarding their man-
ufacturer, source, degree of hydrolysis, protein, and endo-
toxin contents.
The endotoxin levels of the formulas were measured with
Pierce LAL Chromogenic Endotoxin Quantitation Kit
(Thermo Scientific, Vienna, Austria) as described in the user
manual.
Antibody probes specific for the individual CM proteins
were produced as follows: cDNA coding for several CM
Table 1 Characterization of milk formulas M1–M10
Milk
samples Product Manufacturer
Source
(casein or
whey) Condition
Protein
content
(g/100 g)
Endotoxin
content
(EU in 100 lg
protein)
M1 Enfamil
premium
MJN C + W Nonhydrolyzed (NH) 11.00 0.035
M2 Enfamil HA-
Gentlease
MJN C + W Partially (PH) 12.80 0.035
M3 Nutramigen MJN C Extensively (EH) 14.00 0.036
M4 Nutramigen AA MJN AA Amino acids (AA) 14.00 0.041
M5 Nan HA Nestle W Partially (PH) 11.50 0.034
M6 Friso
allergycare
Friso C Extensively (EH) 11.70 0.036
M7 Alimentum
advance
Ross C Extensively (EH) 13.93 0.030
M8 Alfare Nestle W Extensively (EH) 14.80 0.039
M9 Milk protein MJN C + W Whole milk whey
and casein proteins
36.00 0.046
M10 Whey MJN W Whole whey proteins 36.10 0.048
HA, hypoallergenic; MJN, Mead Johnson Nutrition; C, casein; W, whey; AA, amino acids; EH, extensively hydrolyzed; PH, partially hydro-
lyzed.
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allergens were isolated by IgE immunoscreening of a cDNA
expression library prepared from bovine mammary glands
(15). Recombinant CM allergens (alphaS1-casein, alphaS2-
casein, beta-casein, kappa-casein, alpha-lactalbumin, beta-lac-
toglobulin, lactoferrin) were expressed in Escherichia coli
strain BL21 Codon Plus (DE3)-RIPL (Stratagene, La Jolla,
CA, USA) as hexahistidine-tagged proteins and purified by
Ni2+ affinity chromatography (QIAGEN, Hilden, Germany)
as described by Schulmeister et al. (15).
Allergen-specific rabbit antibodies were obtained by immu-
nizing rabbits three times (once in CFA and twice in incom-
plete Freund’s adjuvant (IFA)) with the purified recombinant
proteins (Charles River, Kisslegg, Germany).
Serum and blood samples
Serum and blood samples were obtained from CM-allergic
patients (n = 26), patients who suffered from symptoms after
CM consumption but without CM-specific IgE (n = 2), sub-
jects with CM-specific IgE but without symptoms (n = 4),
and from six nonallergic subjects. The diagnosis of CM
allergy was based on the presence of clinical symptoms that
could be unambiguously attributed to consumption of CM
and/or on results of an open food challenge, a positive skin
prick test reaction, and the presence of specific IgE to CM
allergens as measured by ImmunoCAP (Thermo Fisher Sci-
entific, Uppsala, Sweden) (Table 2). Hypolactasia was not
investigated in the CM-allergic patients because it does not
affect immune reactivity to CM components. In addition to
the CM-allergic subjects, we tested also serum and blood
samples from nonallergic subjects, two patients with symp-
toms upon CM contact (cough, gastrointestinal problems)
lacking CM-specific IgE, and four subjects with CM-specific
IgE without symptoms to CM (Table 2). Serum and blood
samples were analyzed in an anonymized manner with
permission of the Ethics Committee of the Medical Univer-
sity of Vienna (EK565/2007; EK1641/2014). For freshly
taken blood samples, informed written consent was obtained
from the subjects. Clinical and demographic features of the
subjects are summarized in Table 2.
Analysis of formulas by SDS-PAGE and by dot blotting with
specific antibody probes
Protein, peptide, and amino acid contents in the milk formulas
were determined by measuring protein nitrogen in the samples
by the Kjeldahl method (16). Aliquots of 30 lg/lane of the
milk samples were subjected to SDS-PAGE and Coomassie
Brilliant Blue staining (17). For immunoblot analysis, 1 lg ali-
quots of the milk samples were dotted onto a nitrocellulose
membrane (Schleicher & Schuell, Dassel, Germany). Dot blot-
ting instead of Western blotting was chosen in order not to lose
small peptides during gel electrophoresis and electroblotting
and to avoid denaturing conditions that may affect IgE reac-
tivity. The nitrocellulose strips were blocked with PBST (PBS,
0.5% v/v Tween 20) and exposed to rabbit antisera (1 : 2000
diluted) or to sera from CM-allergic patients and nonallergic
individuals (1 : 10 or 1 : 20 diluted) overnight at 4°C. Bound
rabbit IgG antibodies were detected with 125I-labeled donkey
anti-rabbit IgG (Perkin Elmer, Boston, MA, USA) diluted
1 : 2000 in PBST or in the case of human IgE antibodies with
125I-labeled anti-human IgE antibodies (IBL, Hamburg, Ger-
many), diluted 1 : 15. Positive signals were visualized by
autoradiography using Kodak XOMAT films with intensifying
screens (Kodak, Vienna, Austria) at 80°C.
Rat basophil leukemia assays
For the assessment of the allergenic activity of the milk sam-
ples, huRBL cell mediator release assays were performed as
Table 2 Demographic and clinical features of patients and control individuals
Patient Sex M/F Age
Milk-related
symptoms Other allergies Total IgE (kU/l)
Spec. IgE to
CM (kUA/l)
A: Nonallergic
individuals (n = 6)
2/4 21–51 years No No 5.8–91.1 <0.35
B: CM allergic
patients (n = 26)
14/9
3 nk
4 months
to 70 years
AD, AE,
AS diarrhea,
E, eczema GI,
Rh, U, V, Sys
Animal dander,
candida, cat,
dog fish, hazelnut,
HE, mite, moulds
nuts, PO, soy, wheat
3.58–3350 1.3–>100
C: Patients without
CM-specific IgE
but with
symptoms (n = 2)
1/1 25–53 years CO, GI Cat, mite 64.9–153 <0.35
D: Patients with
CM-specific IgE
but without
symptoms (n = 4)
2/2 5–55 years No Birch, HE, PO,
sheep milk
14.1–1844 0.79–7
F, female; M, male; Symptoms: AD, atopic dermatitis; AE, angioedema; AS, asthma; E, edema; GI, gastrointestinal symptoms; Rh, rhinitis;
U, urticaria; V, vomiting; Sys, systemic reactions; CO, cough; Allergen (source): HE, hen’s egg; PO, pollen; kU/l, total IgE in kilo units/liter;
kUA/l, allergen-specific IgE in kilo units antigen/liter; CM, cow’s milk; nk, not known.
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described previously (15, 18). In brief, rat basophil leukemia
(RBL) cells (clone RBL-703/21) transfected with the human
FceRI were incubated with sera from CM-allergic patients
overnight. On the next day, the cells were washed, and
100 ll of milk components (concentration: 0.3 lg/ml total
protein contents) were added and incubated for 1 h at 37°C,
7% CO2, 95% humidity. Aliquots of the supernatants were
mixed with assay solution (0.1 M citric acid or sodium
citrate, pH4.5 and 160 lM 4-methyl umbelliferyl-N-acetyl-b-
D-glucosamide) and incubated for 1 h at 37°C, 7% CO2,
95% humidity. Fluorescence was measured with a fluores-
cence microplate reader, and specific release could be calcu-
lated. Values obtained with buffer alone were subtracted,
and the values exceeding 10% of total release were consid-
ered as positive.
Lymphocyte proliferation assays
PBMCs from six nonallergic individuals and seven CM-aller-
gic patients were isolated from heparinized blood samples by
Ficoll density gradient centrifugation (Amersham Biosciences,
Uppsala, Sweden). PBMCs (2 9 105 cells per well) were cul-
tured in triplicates in 96-well plates (Nunclone; Nalgen Nunc
International, Roskilde, Denmark) in 200 ll serum-free Ultra
Culture medium (BioWhittaker, Rockland, ME, USA) sup-
plemented with 2 mM L-glutamine (Gibco, Carlsbad, CA,
USA), 50 lM b-mercaptoethanol (Gibco), and 0.1 mg gen-
tamicin per 500 ml (Gibco). The cells were incubated at 37°C
in a humidified atmosphere with 5% CO2 for 7 days and
stimulated with different concentrations of milk samples
(0.05, 0.5, 3, and 10 lg/well), 4 U IL-2 per well (Roche) as a
positive control and medium alone as a negative control in
duplicate. After 6 days of incubation, 0.5 mCi 3H-thymidine
(Amersham, Buckinghamshire, UK) was added to each well
for 16 h, and then, the incorporated radioactivity was mea-
sured by liquid scintillation counting. Proliferation was
expressed as counts per minute (c.p.m.; means of triplicates)
using a microbeta scintillation counter (Wallac ADL, Frei-
burg, Germany). The mean stimulation indices (SI) were cal-
culated as quotient of triplicate c.p.m. with antigen vs
medium and shown are the SI obtained by stimulation with
10 lg protein/well.
Analysis of cytokine levels in supernatants
Cytokine levels (IL-5, IL-6, IL-10, IL-13, IFN-c, TNF-a,
GM-CSF) were measured in supernatants collected from
PBMC cultures at day 6 of culture using xMAP Luminex
fluorescent bead-based technology. The assays were per-
formed according to the manufacturer’s instructions (R&D
Systems, Wiesbaden, Germany), and fluorescent signals
were read on a Luminex 100 system (Luminex Corp., Aus-
tin, TX, USA). The limits of detection were 1.9 pg/ml for
IL-5, 5.5 pg/ml for IL-6, 3.1 pg/ml for IL-10, 47 pg/ml for
IL-13, 2.9 pg/ml for IFN-c, 5.3 pg/ml for TNF-a, and
3.3 pg/ml for GM-CSF. Shown are means of triplicate
determinations from cultures stimulated with 10 lg protein/
well.
Statistics
Statistical comparisons were performed by Mann–Whitney
U-test for nonparametric values. P-values < 0.05 were con-
sidered as significant. For all calculations, the statistical pro-
gram PASW Statistics 18 (Version 18.0.0. 1993–2007; Polar
Engineering and Consulting Nikiski, Alaska, United States)
was used.
Results
Biochemical and immunochemical analysis indicates different
compositions of milk formulas
In the first step, formulas M1 to M10 were analyzed by SDS-
PAGE and stained with Coomassie Brilliant Blue to visualize
intact proteins. This analysis demonstrated the presence of
several proteins with molecular masses between 10 and
100 kDa in the formulas M1, M9, and M10 and to lesser
extent in M3 (Fig. 1A). Protein smears below 20 kDa were
found in M2 and M5, whereas in M4, M6, M7, and M8, no
protein staining was observed (Fig. 1A). The measurement of
the endotoxin levels in the 10 samples showed low levels of
endotoxin (<0.05 EU in 100 lg protein) (Table 1).
In the next step, we used specific antisera raised against
purified recombinant CM allergens (raS1-cas, raS2-cas, rb-
cas, rk-cas, ra-la, rb-lg, rlf) to detect immunoreactive compo-
nents in the formulas in dot blot experiments (Fig. 1B). The
whole CM protein-containing formula M1 and the milk
protein control M9 reacted with each of the antisera demon-
strating the presence of the proteins of the casein fraction
(aS1-cas, aS2-cas, b-cas, k-cas) and from the whey fraction
(a-la, b-lg, lf). In M2, a PH formula that is made up from
casein and whey, mainly a-la and b-lg and to a much lower
degree, aS2-cas was detected. The other PH formula M5 also
contained immunoreactive a-la and b-lg. Interestingly, the
EH formula M8 that is produced of the whey fraction con-
tains mainly the immunoreactive caseins but whey protein
could not be detected. In the whey fraction M10, each of the
whey proteins (i.e. a-la, b-lg, and lactoferrin) was detected.
No immunoreactive proteins of the casein and whey fraction
were detected in the formulas M3, M4, M6, and M7.
Milk formulas show major differences regarding IgE
reactivity and allergenic activity
In the next step, the IgE reactivities of the samples were
tested with a highly sensitive RAST-based dot blot analysis
using sera from 21 CM-allergic patients, two patients with
symptoms after CM consumption lacking milk-specific IgE, a
nonallergic control, and four patients with CM-specific IgE
antibodies but without symptoms (Fig. 2). Almost each of
the 21 CM-allergic patients showed IgE reactivity to M1,
M9, and M10. There were differences regarding IgE reactiv-
ity to M1, M9, and M10, which may be attributed to a dif-
ferent sensitization of the patients to caseins and whey
proteins. IgE reactivity to M8 was found for patients 7, 8,
12, 13, 16, 18, 19, 21, and 22 (Fig. 2). Patients 1, 5, 7, 8, 19,
Allergy 72 (2017) 416–424 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd. 419
Hochwallner et al. Milk formulas differ in allergenic activity
20, 21, and 22 reacted with M2. Patient 19 and 17 showed
weak IgE reactivity to M5 and M7, respectively (Fig. 2).
Patients 8 and 17 showed reactivity to M7. None of the other
formulas M3, M4, and M6 showed relevant IgE reactivity.
The control serum from the nonallergic person 25 showed no
IgE reactivity to any of the dotted formulas (Fig. 2).
The assessment of the allergenic activity of the milk formu-
las by basophil degranulation experiments was in quite good
agreement with the IgE reactivity data. We found that
mainly the samples M1, M9, and M10 induced mediator
release in CM-allergic patients. Furthermore, M8 induced
degranulation in cells loaded with sera from patients 19 and
22 (data not shown).
Different capacity of milk formulas to induce lymphocyte
proliferation
Next, we tested the ability of the milk formulas to induce
lymphocyte proliferation in cultured PBMCs from seven
CM-allergic and six nonallergic individuals (Fig. 3). Except
for the whole milk preparation M9, nonhydrolyzed (M1,
M10) and PH formulas (M2, M5) showed the highest median
SI (M1: nonallergic: SI 5.3, CM allergic: SI 4.3; M2: nonal-
lergic: SI 4.5, CM allergic: SI 2.6; M5: nonallergic: SI 3.9,
CM allergic: SI 2.7, M9: nonallergic: SI 2.1, CM allergic: SI
1.8) (Fig. 3). Among the EH formulas, the median SI were
higher for M6 (nonallergic: SI 3.3, CM allergic: SI 1.6) and
Figure 1 (A) Detection of proteins in milk formulas M1–M10 by
SDS-PAGE and Coomassie Brilliant Blue Staining. Aliquots of each
milk formula (lanes M1–M10) were loaded. Lanes M show molecular
weight markers (kDa). (B) Reactivity of M1–10 with specific antibody
probes. Aliquots of the samples were dotted in duplicates onto
nitrocellulose and incubated with rabbit antibodies raised against
recombinant cow’s milk (CM) proteins (raS1-cas, raS2-cas, rb-cas,
rj-cas, ra-la, rb-lg, rlf), with normal rabbit serum (nrs) or with buffer
alone. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2 IgE reactivity of dot-blotted milk samples M1–M10. Ali-
quots of the sample were dotted in duplicates onto nitrocellulose
and incubated with buffer alone, with sera from cow’s milk (CM)-
allergic patients (1, 3–22), with sera from subjects who had
problems after milk consumption but lacked CM-specific IgE (23,
24), with serum from a nonallergic control (25), and with sensitized
individuals who had CM-specific IgE without symptoms (2, 26–28).
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M7 (nonallergic: SI 2.9, CM allergic: SI 1.8), whereas M3
(nonallergic: SI 1.4, CM allergic: SI 1.3) and M8 (nonallergic:
SI 1.1, CM allergic: SI 1.0) revealed lowest proliferation. The
proliferation induced with M3 and M8 was as low as that
obtained for the amino acid formulation M4 (nonallergic: SI
1.3, CM allergic: SI 1.1). It was interesting to note that milk
formulas containing immunoreactive whey proteins (Fig. 1B:
M1, M2, M5, M9, and M10) showed higher lymphocyte pro-
liferation than the milk formula containing only caseins
(Fig. 1B: M8). There were no statistical significant differences
between the median SI observed for milk allergic and nonal-
lergic individuals except for M6 with nonallergic individuals
showing significantly higher SI (Fig. 3, P < 0.024).
Identification of milk formulas that induce low levels of
proinflammatory cytokines
The PBMC culture supernatants from nonallergic individuals
and CM-allergic patients stimulated with the milk formulas
M1–M10 were analyzed regarding the secretion of various
cytokines by Luminex analysis (Fig. 4). The EH formulas
M3 and M6 and the amino acid formulation M4 were the
milk formulas that induced low levels of all tested cytokines.
Similarly, the EH formula M8 induces low levels for most
cytokines except for IL-5.
When taking a closer look at the Th2 cytokines such as
IL-5 (Fig. 4A) and IL-13 (Fig. 4B), the following observa-
tions were made: First, all but M6 induced IL-13. There were
no significant differences between CM allergic and nonaller-
gic subjects regarding the levels of IL-5 and IL-13 in the
stimulated cultures (Fig. 4A,B). Second, M2, a PH formula,
induced IL-5 and IL-13 as strongly as the nonhydrolyzed for-
mula M1, whereas the other formulas were less active
(Fig. 4A,B).
Similar findings were made for GM-CSF. Again, M1 and
M2 induced high levels of GM-CSF, but in this case, also the
other PH formula M5, and M10, the whole whey proteins,
induced high levels of GM-CSF (Fig. 4C). Another difference
as compared to IL-5 and IL-13 was that for all formulas but
M5, GM-CSF levels were lower in PBMC cultures of allergic
patients, although this was not statistically significant.
Next, we analyzed the proinflammatory cytokines IL-6 and
TNF-a that gave similar profiles for the different formulas.
The highest levels of IL-6 and TNF-a were found for formu-
las containing complete proteins (i.e. M1, M10), and the PH
formulas M2 and M5 and, interestingly, also the EH formula
M7 induced high levels of these cytokines (Fig. 4D,E). There
was however one difference: IL-6 levels were higher in PBMC
cultures of nonallergic subjects than in cultures of allergic
patients, whereas no such differences were noted for TNF-a
(Fig. 4D,E).
Regarding the Th1 cytokine IFN-c, we found that IFN-c
levels were always higher in PBMC cultures from nonallergic
subjects (Fig. 4F). Again, formulas containing complete pro-
teins (M1, M10) but also the PH formulas M2 and M5
induced the highest levels of IFN-c, followed by the EH for-
mulas M6, M7, and the whole milk sample M9 (Fig. 4F).
For the IL-10, different profiles were observed: The highest
levels of IL-10 were induced by the PH formula M5 and the
complete whey proteins M10 (Fig. 4G). For M5 and M10, we
did not find significant differences between allergic and nonal-
lergic subjects. By contrast, IL-10 levels were always lower for
each of the other tested formulas in allergic subjects.
In summary, the EH formulas M3 and M6 as well as the
amino acid formulation M4 were the formulas which induced
the least allergic/proinflammatory cytokine production in
PBMCs from allergic as well as nonallergic subjects.
Discussion
Hydrolyzed CM formulas are used widely in the diet of CM-
allergic children to prevent allergic reactions and for the pre-
vention of allergic sensitization and allergy development in
high-risk children. Here, we performed a blinded analysis of
10 different CM formulas regarding the presence of immune-
reactive CM allergens/allergen fragments, IgE reactivity,
allergenic activity, ability to stimulate T-cell responses, and
the secretion of a panel of different cytokines. In fact, hydro-
lyzed CM formulas have been tested already earlier regarding
IgE reactivity, allergenic activity, and in vivo allergenicity (19,
20), but the results of our study revealed some additional
interesting aspects. It is assumed that extensively hydrolyzed
CM formulas are less IgE-reactive and allergenic (10). Fur-
thermore, it has been shown that EH formulas exhibit lower
antigenicity and allergenicity when fed to infants than PH
CM formulas (21). However, our analysis demonstrates that
M1 M2 M3 M10M9M8M7M6M5M4
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Figure 3 Lymphoproliferative responses in PBMCs induced by
milk formulas M1–M10. PBMCs from six nonallergic individuals
and from seven cow’s milk (CM)-allergic patients were stimulated
with milk formulas (M1–M10) (x-axis). Box plots of stimulation
indices with indicated medians for nonallergic (white) and allergic
subjects (gray) are displayed (y-axis). Asterisks are extreme out-
liers, and circles represent mild outliers. *Statistical significant dif-
ference (P < 0.05).
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certain EH formulas (e.g. M7, M8) similar as PH formulas
(M2, M5) exhibited remaining IgE reactivity and/or aller-
genic activity in basophil activation assays. Another interest-
ing observation was that with the use of antibody probes
specific for certain CM allergens, immune-reactive casein
fragments were detected in formula M8 that was prepared
from whey. It is thus quite likely that the residual IgE reac-
tivity and allergenic activity of this formula was due to the
presence of remaining allergenic casein-derived material. In
fact, a similar finding was made recently by authors who
studied time courses of whey hydrolysis and actually found
that even after prolonged hydrolysis, patients showed IgE
reactivity to caseins in the preparations (22). It is thus possi-
ble that hydrolyzed whey preparations may contain casein-
derived peptides because they are less well hydrolyzed than
the whey components.
The analysis of the capacity of the formulas to induce T-cell
proliferation and cytokine secretion showed further
differences among the formulas. The results of the T-cell pro-
liferation experiments yielded similar results as observed
earlier, in that PH formulas induced T-cell proliferation
almost to the same extent as formulas containing complete
allergen (23). However, only two of the four EH formulas
(M3, M4) showed basically no remaining T-cell reactivity such
as the amino acid formulation and thus proved to be non-T-
cell stimulatory. Cow’s milk formulas in which immune-reac-
tive whey proteins were detected (i.e. M1, M2, M5, and M10)
induced higher lymphocyte proliferation than the formula
containing only caseins (i.e. M8). Interestingly, there were no
relevant differences regarding the induction of T-cell prolifera-
tion between CM-allergic and nonallergic individuals. As the
CM formulas are natural products, it cannot be excluded that
carbohydrates or lipids in the formulas had an influence on
the cellular responses but it is unlikely because proteins/pep-
tides represent the major constituents of the CM formulas and
the endotoxin levels in the preparations were very low.
The perhaps most interesting results came from the analy-
sis of the induction of cytokines upon stimulation of PBMC
with the CM formulas. In fact, we noted significant differ-
ences of the CM formulas to induce Th2, Th1, and proin-
flammatory cytokine responses. There were also significant
differences regarding the production of proinflammatory
cytokines such as IL-6 and the Th1 cytokine IFN-c between
allergic and nonallergic individuals. PBMC from nonallergic
individuals secreted higher levels of IL-6 and IFN-c than
PBMCs from allergic individuals. It is possible that the
proinflammatory cytokines are not exclusively derived from
T cells, but this will reflect in vivo conditions where also other
cell types are present similar as in PBMCs.
Most importantly, we found that three formulas (EH: M3
and M6; amino acid formulation: M4) did not induce any
relevant levels of Th1, Th2, or proinflammatory cytokines,
neither in PBMCs of allergic or nonallergic patients. This
finding can most likely be explained by the lack of immune-
stimulatory peptides in these formulas which is consistent
with the observation that they also did not stimulate T-cell
proliferation. Interestingly, the formula M3 had been shown
in the long-term German Infant Nutritional Intervention
Study (GINI) to reduce the risk of developing AD, a T-cell-
driven allergic skin manifestation (11). However, it must be
noted that it is presently not clear if the induction of proin-
flammatory cytokines in PBMC samples is related to clinical
symptoms.
In summary, our results demonstrate that there are strik-
ing differences among hydrolyzed CM formulas regarding
IgE reactivity, allergenic activity, and the ability to induce
proinflammatory immune responses. It is quite possible that
some of the discrepancies observed in clinical intervention
trials and in the course of the clinical use of CM formulas
for the prevention and treatment of CM allergy could be
due to differences in the immunological and/or immunomo-
dulatory properties of the various available preparations. It
would thus seem to make sense to agree on common stan-
dardization protocols for the various CM formulas (24) sim-
ilar as are used for example for standardization of
diagnostic and therapeutic allergen extracts (25).
The finding that it is possible to identify CM formulas
without allergenic activity and no proinflammatory activity
makes it tempting to speculate that such formulas might be
useful not only for the prevention of CM allergy but
maybe also for other inflammatory diseases. In this context,
it has been suggested that inflammation in the gut and
inflammatory processes leading to defects in the mucosal
gut barrier may contribute to local and systemic autoimmu-
nity (26–30).
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